Abstract
Introduction: Ambulatory pneumothorax (PTX) management saves inpatient days and is feasible with the Rocket pleural vent (PV) at the expense of higher rate of complications in primary spontaneous pneumothorax (PSP) (1). The HiSPec study (2) in secondary spontaneous pneumothorax (SSP) showed that PV was probably dangerous. We have a local service with strict inclusion criteria (WHO PS 0-2, ambulant patients).
Methods: We retrospectively analysed all PTX managed with a PV from March 2018 - January 2021.
Results: 49 patients were identified. Figure 1 shows the characteristics of 31 patients with PSP and 16 patients with SSP managed with the PV. Figure 2 shows the adverse events related to those vents. Total number of bed days saved are 262 beds.
Conclusions: Complication rates were less than the RAMPP trial and commoner with PSP patients. There is no indication of the PV being unsafe in SSP, but our cohort is highly selective and thus at risk of significant bias.
References: 1. https://doi.org/10.1016/S0140-6736(20)31043-6 2. https://erj.ersjournals.com/content/early/2020/11/26/13993003.03375-2020
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3791.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
